New cancer staging system put to the test in chinese patients
NCT ID NCT07088861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the newest version of the cancer staging system (TNM-9) accurately predicts outcomes for people with nasopharyngeal carcinoma in parts of China where the disease is less common. Researchers will review medical records from about 1,400 patients treated between 2011 and 2023. The goal is to see if the new system helps doctors better plan treatment and understand patient prognosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dual-Action antibody may boost chemoradiotherapy against High-Risk nasopharyngeal cancer
- Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer
- New risk model may let some NPC patients avoid unnecessary chemo
- New proton therapy trial aims to reduce side effects in nasopharyngeal cancer